Specifically in the NSCLC cohort, treatment-naïve patients achieved a DCR of 86.7% (13/15), and patients treated with a prior KRAS G12C inhibitor achieved a DCR of 66.7% (2/3). Here, KRAS is linked to non-small cell lung carcinoma.